Evidence map›Paper›PMID 7791794›Full record

ArticleMolecular and cellular biology1995

Characterization of promoter elements required for cell-specific expression of the neurotensin/neuromedin N gene in a human endocrine cell line.

B M Evers, X Wang, Z Zhou, C M Townsend, G P McNeil, P R Dobner

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

B M EversDepartment of Surgery, The University of Texas Medical Branch, Galveston 77555, USA.
X Wang
Z Zhou
C M Townsend
G P McNeil
P R Dobner
University of Massachusetts Chan Medical School · US

Funding

TISSUE CULTURE COREP01DK035608 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI HELLMICH, MARK R · 1986 to 2010
$14.0M
Surgical Studies of Ontogeny, Aging and the GutR37AG010885 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI EVERS, BERNARD MARK · 2002 to 2011
$3.6M
SURGICAL STUDIES OF ONTOGENY, AGING AND THE GUTR01AG010885 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI EVERS, BERNARD MARK · 1997 to 2001
$498k
NEUROTENSIN GENE REGULATION IN NEURAL CREST DERIVED CELLR01HL033307 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DOBNER, PAUL RICHARD · 1988 to 1994
–
STUDIES OF NEUROTENSIN GENE STRUCTURE AND REGULATIONR23HL033307 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DOBNER, PAUL RICHARD · 1985 to 1987
–
SURGICAL STUDIES OF ONTOGENY, AGING AND THE GUTR29AG010885 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI EVERS, BERNARD MARK · 1992 to 1996
–
NHLBI NIH HHS HL33307NIA NIH HHS AG10885NIDDK NIH HHS DK35608
6 · The paper itself

Abstract

Expression of the gene encoding neurotensin/neuromedin N (NT/N) is mostly limited to the brain and specialized enteroendocrine cells (N cells) of the distal small intestine. We have analyzed the NT/N DNA sequences upstream of the RNA start site that direct cell-specific expression using a novel human endocrine cell line, BON, that resembles intestinal N cells in several important aspects, including NT/N precursor protein processing, ratios of different NT/N mRNA forms, and high levels of constitutive expression of the NT/N gene. Transient transfection assays with plasmids with progressive 5' deletions of the rat NT/N promoter identified the proximal 216 bp of 5' flanking sequences as essential for high-level constitutive NT/N expression in BON cells. In addition, a detailed mutational analysis defined multiple regions within the proximal 216 bp that contribute to cell-specific NT/N expression. These elements include a proximal cyclic AMP response element (CRE)/AP-1-like motif (TGACATCA) that binds c-Jun, JunD, CRE-binding (CREB), and ATF proteins, a near-consensus glucocorticoid response element, and a distal consensus AP-1 site that binds c-Fos, Fra-1, and JunD. In addition, elements contained within two 21-bp imperfect direct repeats play an important role in NT/N expression in BON cells and may bind novel factors that act as positive regulators of NT/N expression. DNase I footprinting and gel shift analyses demonstrate that the sites identified by mutational analysis, and at least one additional site, specifically bind BON cell nuclear proteins in vitro. We speculate that a complex pattern of regulation requiring interaction between a proximal CRE/AP-1-like motif and other upstream control elements play an important role in the high-level constitutive expression of NT/N in the human endocrine cell line BON. In addition, the BON cell line provides a unique model to further characterize the factors regulating cell-specific NT/N expression and to better understand the mechanisms responsible for the terminal differentiation of the N-cell lineage in the gut.

Indexed as

Gene Expression Regulation, NeoplasticActivating Transcription Factor 1Activating Transcription Factor 2AdenocarcinomaAnimalsBase SequenceBinding, CompetitiveCyclic AMP Response Element-Binding ProteinDNA-Binding ProteinsDNA Mutational AnalysisFos-Related Antigen 1HumansMolecular Sequence DataNeurotensinPancreatic NeoplasmsPeptide FragmentsActivating Transcription Factor 1Activating Transcription Factor 2Cyclic AMP Response Element-Binding ProteinDNA-Binding ProteinsFos-Related Antigen 1neuromedin NNeurotensinPeptide FragmentsProto-Oncogene Proteins c-fosProto-Oncogene Proteins c-junTranscription Factors

Identifiers

PMID7791794
PMCPMC230627
OpenAlexW2149842264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.